keyword
MENU ▼
Read by QxMD icon Read
search

Children oncology group

keyword
https://www.readbyqxmd.com/read/29788429/corticosteroid-use-endpoints-in-neuro-oncology-response-assessment-in-neuro-oncology-working-group
#1
Nils D Arvold, Terri S Armstrong, Katherine E Warren, Susan M Chang, Lisa M DeAngelis, Jaishri Blakeley, Marc C Chamberlain, Erin Dunbar, Herbert H Loong, David R Macdonald, David A Reardon, Michael A Vogelbaum, Ying Yuan, Michael Weller, Martin van den Bent, Patrick Y Wen
Background: Corticosteroids are the mainstay of treatment for peritumor edema but are often associated with significant side effects. Therapies that can reduce corticosteroid use would potentially be of significant benefit to patients. However, currently there are no standardized endpoints evaluating corticosteroid use in neuro-oncology clinical trials. Methods: The Response Assessment in Neuro-Oncology (RANO) Working Group has developed consensus recommendations for endpoints evaluating corticosteroid use in clinical trials in both adults and children with brain tumors...
May 18, 2018: Neuro-oncology
https://www.readbyqxmd.com/read/29781567/localized-vaginal-uterine-rhabdomyosarcoma-results-of-a-pooled-analysis-from-four-international-cooperative-groups
#2
Veronique Minard-Colin, David Walterhouse, Gianni Bisogno, Helene Martelli, James Anderson, David A Rodeberg, Andrea Ferrari, Meriel Jenney, Suzanne Wolden, Gianluca De Salvo, Carola Arndt, Johannes H M Merks, Soledad Gallego, Dominique Schwob, Christine Haie-Meder, Christophe Bergeron, Michael C G Stevens, Odile Oberlin, Douglas Hawkins
BACKGROUND: Vaginal/uterine rhabdomyosarcoma (VU RMS) is one of the most favorable RMS sites. To determine the optimal therapy, the experience of four cooperative groups (Children's Oncology Group [COG], International Society of Pediatric Oncology (SIOP) Malignant Mesenchymal Tumor Group [MMT], Italian Cooperative Soft Tissue Sarcoma Group [ICG], and European pediatric Soft tissue sarcoma Study Group [EpSSG]) was analyzed. PROCEDURE: From 1981 to 2009, 237 patients were identified...
May 21, 2018: Pediatric Blood & Cancer
https://www.readbyqxmd.com/read/29774474/perspectives-of-children-family-caregivers-and-health-professionals-about-pediatric-oncology-symptoms-a-systematic-review
#3
REVIEW
Lei Cheng, Liying Wang, Mengxue He, Sheng Feng, Yehui Zhu, Cheryl Rodgers
OBJECTIVES: To evaluate the existing body of evidence to determine the current state of knowledge regarding the perspectives of the following groups: (1) children with cancer, (2) family caregivers, and (3) healthcare professionals, about symptoms, as well as factors that may influence the symptom reports. METHODS: A systematic search was performed for all types of studies that included the perspectives of at least two groups of participants' symptom reports. Children included anyone younger than 19 years of age who was diagnosed with any type of cancer...
May 17, 2018: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
https://www.readbyqxmd.com/read/29769263/how-i-treat-burkitt-lymphoma-in-children-adolescents-and-young-adults-in-sub-saharan-africa
#4
Satish Gopal, Thomas G Gross
Burkitt lymphoma (BL) is the most common pediatric cancer in sub-Saharan Africa (SSA), and also occurs frequently among adolescents and young adults (AYA), often associated with human immunodeficiency virus (HIV). Treating BL in SSA poses particular challenges. Although highly effective, high-intensity cytotoxic treatments used in resource-rich settings are usually not feasible, and lower-intensity continuous infusion approaches are impractical. In this paper, based on evidence from the region, we review management strategies for SSA focused on diagnosis, use of pre-phase, and definitive treatment...
May 16, 2018: Blood
https://www.readbyqxmd.com/read/29767345/metastatic-breast-cancer-collateral-damage-project-mbccd-scale-development-and-preliminary-results-of-the-survey-of-health-impact-needs-and-experiences-shine
#5
Timothy J Williamson, Susan M Love, Jessica N Clague DeHart, Alexandra Jorge-Miller, Leah Eshraghi, Heather Cooper Ortner, Annette L Stanton
PURPOSE: Until recently, people with metastatic breast cancer (MBC) had a very poor prognosis. New treatment approaches have prolonged the time that people with MBC live, but their quality of life has received less attention. Consequently, the needs and concerns across financial, vocational, psychological, social, and physical domains in MBC patients are poorly understood-particularly regarding the collateral damage or longer-term, life-altering impacts of MBC and its treatments. This study's aims were to characterize MBC-related collateral damage, identify groups most likely to experience collateral damage, and examine its associations with psychological health, illness management, and health behaviors...
May 16, 2018: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/29754509/-new-and-traditional-directions-in-the-biology-and-management-of-childhood-acute-lymphoblastic-leukemia
#6
Bálint Egyed, Gábor Kovács, Nóra Kutszegi, Andrea Rzepiel, Judit Csányiné Sági, Dániel János Erdélyi, Judit Müller, Ágnes Félné Semsei
Owing to clinical trials and improvement over the past few decades, the majority of children with acute lymphoblastic leukemia (ALL) survive by first-line chemotherapy and combat with the problems of returning to community. However, many patients may have severe acute or late therapeutic side effects, and the survival rate in some groups (e.g., patients with MLL rearrangements, hypodiploidy, IKZF1 mutation or early precursor T cell phenotype) is far behind the average. Innovative strategies in medical attendance provide better clinical outcomes for them: complete gene diagnostics, molecularly targeted anticancer treatment, immuno-oncology and immune cell therapy...
May 2018: Orvosi Hetilap
https://www.readbyqxmd.com/read/29753700/spectrum-and-prevalence-of-genetic-predisposition-in-medulloblastoma-a-retrospective-genetic-study-and-prospective-validation-in-a-clinical-trial-cohort
#7
Sebastian M Waszak, Paul A Northcott, Ivo Buchhalter, Giles W Robinson, Christian Sutter, Susanne Groebner, Kerstin B Grund, Laurence Brugières, David T W Jones, Kristian W Pajtler, A Sorana Morrissy, Marcel Kool, Dominik Sturm, Lukas Chavez, Aurelie Ernst, Sebastian Brabetz, Michael Hain, Thomas Zichner, Maia Segura-Wang, Joachim Weischenfeldt, Tobias Rausch, Balca R Mardin, Xin Zhou, Cristina Baciu, Christian Lawerenz, Jennifer A Chan, Pascale Varlet, Lea Guerrini-Rousseau, Daniel W Fults, Wiesława Grajkowska, Peter Hauser, Nada Jabado, Young-Shin Ra, Karel Zitterbart, Suyash S Shringarpure, Francisco M De La Vega, Carlos D Bustamante, Ho-Keung Ng, Arie Perry, Tobey J MacDonald, Pablo Hernáiz Driever, Anne E Bendel, Daniel C Bowers, Geoffrey McCowage, Murali M Chintagumpala, Richard Cohn, Timothy Hassall, Gudrun Fleischhack, Tone Eggen, Finn Wesenberg, Maria Feychting, Birgitta Lannering, Joachim Schüz, Christoffer Johansen, Tina V Andersen, Martin Röösli, Claudia E Kuehni, Michael Grotzer, Kristina Kjaerheim, Camelia M Monoranu, Tenley C Archer, Elizabeth Duke, Scott L Pomeroy, Redmond Shelagh, Stephan Frank, David Sumerauer, Wolfram Scheurlen, Marina V Ryzhova, Till Milde, Christian P Kratz, David Samuel, Jinghui Zhang, David A Solomon, Marco Marra, Roland Eils, Claus R Bartram, Katja von Hoff, Stefan Rutkowski, Vijay Ramaswamy, Richard J Gilbertson, Andrey Korshunov, Michael D Taylor, Peter Lichter, David Malkin, Amar Gajjar, Jan O Korbel, Stefan M Pfister
BACKGROUND: Medulloblastoma is associated with rare hereditary cancer predisposition syndromes; however, consensus medulloblastoma predisposition genes have not been defined and screening guidelines for genetic counselling and testing for paediatric patients are not available. We aimed to assess and define these genes to provide evidence for future screening guidelines. METHODS: In this international, multicentre study, we analysed patients with medulloblastoma from retrospective cohorts (International Cancer Genome Consortium [ICGC] PedBrain, Medulloblastoma Advanced Genomics International Consortium [MAGIC], and the CEFALO series) and from prospective cohorts from four clinical studies (SJMB03, SJMB12, SJYC07, and I-HIT-MED)...
May 9, 2018: Lancet Oncology
https://www.readbyqxmd.com/read/29752854/perioperative-factors-associated-with-persistent-opioid-use-after-extensive-abdominal-surgery-in-children-and-adolescents-a-retrospective-cohort-study
#8
Pascal Owusu-Agyemang, Juan P Cata, Antoinette Van Meter, Ravish Kapoor, Acsa M Zavala, Uduak U Williams, January Tsai, Elizabeth Rebello, Lei Feng, Andrea Hayes-Jordan
BACKGROUND: In adults, preoperative opioid use and higher perioperative opioid consumption have been associated with higher odds of persistent opioid use after surgery. There are limited data on the prevalence and factors associated with persistent opioid use after major oncologic surgery in children. AIMS: In this study, we sought to determine the prevalence and factors associated with the development of persistent opioid use in a group of children and adolescents who had undergone cytoreductive surgery with hyperthermic intraperitoneal chemotherapy...
May 12, 2018: Paediatric Anaesthesia
https://www.readbyqxmd.com/read/29738613/results-of-the-ahod0431-trial-of-response-adapted-therapy-and-a-salvage-strategy-for-limited-stage-classical-hodgkin-lymphoma-a-report-from-the-children-s-oncology-group
#9
Frank G Keller, Sharon M Castellino, Lu Chen, Qinglin Pei, Stephan D Voss, Kathleen M McCarten, Stacy L Senn, Allen B Buxton, Rizvan Bush, Louis S Constine, Cindy L Schwartz
BACKGROUND: The Children's Oncology Group AHOD0431 study evaluated a response-directed treatment paradigm in which minimal initial chemotherapy and low-dose radiation was received only by patients who did not achieve a complete remission, and a chemotherapy/low-dose radiation salvage regimen was received by those who had a protocol-defined, low-risk recurrence. METHODS: Patients younger than 21 years who had stage IA or IIA nonbulky disease were eligible. The treatment strategy was evaluated by determining the proportion that received minimal chemotherapy alone, the proportion that had a first or second remission without the receipt of high-dose chemotherapy/stem cell rescue or higher dose involved-field radiation therapy (>21 grays), and overall survival...
May 8, 2018: Cancer
https://www.readbyqxmd.com/read/29727056/a-comparison-of-ketamine-midazolam-to-propofol-for-procedural-sedation-for-lumbar-puncture-in-pediatric-oncology-by-nonanesthesiologists-a-randomized-comparative-trial
#10
Varsha Chayapathi, Manas Kalra, Anita S Bakshi, Amita Mahajan
BACKGROUND: Both ketamine-midazolam and propofol are frequently used in pediatric oncology units for procedural sedation. However, there are no prospective, randomized comparative trials (RCT) comparing the two groups when the procedure is performed by nonanesthesiologists. OBJECTIVE: To compare ketamine + midazolam (group A) and propofol (group B) as sedative agents for intrathecal chemotherapy with regard to efficacy, side effects, time to induction, time to recovery, and smoothness of recovery...
May 4, 2018: Pediatric Blood & Cancer
https://www.readbyqxmd.com/read/29727048/multicenter-randomized-double-blind-controlled-trial-to-evaluate-the-efficacy-of-laser-therapy-for-the-treatment-of-severe-oral-mucositis-induced-by-chemotherapy-in-children-lampo-rct
#11
Margherita Gobbo, Federico Verzegnassi, Luca Ronfani, Davide Zanon, Fraia Melchionda, Simone Bagattoni, Alessandra Majorana, Elena Bardellini, Rosamaria Mura, Alessandra Piras, Maria Grazia Petris, Maria Livia Mariuzzi, Angelica Barone, Elisabetta Merigo, Nunzia Decembrino, Marina Consuelo Vitale, Massimo Berger, Patrizia Defabianis, Matteo Biasotto, Giulia Ottaviani, Giulio Andrea Zanazzo
OBJECTIVES: To demonstrate the efficacy of laser photobiomodulation (PBM) compared to that of placebo on severe oral mucositis (OM) in pediatric oncology patients. The primary objective was the reduction of OM grade (World Health Organization [WHO] scale) 7 days after starting PBM. Secondary objectives were reduction of pain, analgesic consumption, and incidence of side effects. METHODS: One hundred and one children with WHO grade > 2 chemotherapy-induced OM were enrolled in eight Italian hospitals...
May 4, 2018: Pediatric Blood & Cancer
https://www.readbyqxmd.com/read/29727043/efficacy-and-safety-of-recombinant-e-coli-asparaginase-in-children-with-previously-untreated-acute-lymphoblastic-leukemia-a-randomized-multicenter-study-of-the-dutch-childhood-oncology-group
#12
Inge M van der Sluis, Hester de Groot-Kruseman, Maroeska Te Loo, Wim J E Tissing, Cor van den Bos, Gertjan J L Kaspers, Marc Bierings, Wouter J W Kollen, Thorsten König, Uwe Pichlmeier, Hans-Jürgen Kühnel, Rob Pieters
BACKGROUND: The efficacy and safety of recombinant Escherichia coli-asparaginase (rASNase) was compared to native E.coli asparaginase (Asparaginase medac). METHODS: One hundred and ninety-nine children with newly diagnosed acute lymphoblastic leukemia were randomized to receive one of both agents at a dose of 5,000 U/m² during induction (eight doses) and 10,000 U/m² during the postinduction phase (only high-risk patients; standard- and medium-risk patients received pegaspargase)...
May 4, 2018: Pediatric Blood & Cancer
https://www.readbyqxmd.com/read/29722656/patterns-of-involved-field-radiation-therapy-protocol-deviations-in-pediatric-versus-adolescent-and-young-adults-with-hodgkin-lymphoma-a-report-from-the-children-s-oncology-group-ahod0031
#13
Aaron Parzuchowski, Rizvan Bush, Qinglin Pei, Debra L Friedman, Thomas J FitzGerald, Suzanne L Wolden, Kavita V Dharmarajan, Louis S Constine, Fran Laurie, Sandy K Kessel, Burton Appel, Karen Fernandez, Angela Punnett, Cindy L Schwartz, Jacob Cox, Stephanie A Terezakis
PURPOSE: The presented protocol for pediatric intermediate-risk Hodgkin lymphoma evaluated the use of a dose-intensive chemotherapy regimen (ABVE-PC [doxorubicin, bleomycin, vincristine, etoposide, cyclophosphamide, prednisone]) with response-based therapy augmentation (addition of DECA [dexamethasone, etoposide, cisplatin, cytarabine]) or therapy reduction (elimination of radiation). METHODS AND MATERIALS: A central review of the radiation therapy data for quality assurance was performed, and the association between radiation protocol deviation (RPD) and relapse was assessed in the pediatric group (age <15 years) and adolescent and young adult (AYA) group (age ≥15-21 years)...
April 1, 2018: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/29720909/use-of-individual-pharmacokinetics-to-improve-time-to-therapeutic-vancomycin-trough-in-pediatric-oncology-patients
#14
Calvin L Miller, S Alexander Winans, John J Veillette, Steven C Forland
OBJECTIVE: Optimization of vancomycin dosing is difficult in children, given rapid drug clearance and patient heterogeneity. We sought to evaluate the impact of dosing using individual pharmacokinetic parameters on time to goal trough concentration in pediatric oncology patients. METHODS: A retrospective review was conducted to assess vancomycin dosing in the pediatric oncology unit at Loma Linda University Children's Hospital between January 2013 and August 2013 (standard dosing group [SDG])...
March 2018: Journal of Pediatric Pharmacology and Therapeutics: JPPT: the Official Journal of PPAG
https://www.readbyqxmd.com/read/29719113/a-phase-1-study-of-eribulin-mesylate-e7389-a-novel-microtubule-targeting-chemotherapeutic-agent-in-children-with-refractory-or-recurrent-solid-tumors-a-children-s-oncology-group-phase-1-consortium-study-advl1314
#15
Eric S Schafer, Rachel E Rau, Stacey Berg, Xiaowei Liu, Charles G Minard, David D'Adamo, Rachael Scott, Larisa Reyderman, Gresel Martinez, Sandhya Devarajan, Joel M Reid, Elizabeth Fox, Brenda J Weigel, Susan M Blaney
BACKGROUND: Eribulin mesylate is a novel anticancer agent that inhibits microtubule growth, without effects on shortening, and promotes nonproductive tubulin aggregate formation. We performed a phase 1 trial to determine the dose-limiting toxicities (DLTs), maximum tolerated or recommended phase 2 dose (MTD/RP2D), and pharmacokinetics (PK) of eribulin in children with refractory or recurrent solid (excluding central nervous system) tumors. METHODS: Eribulin was administered intravenously on days 1 and 8 in 21-day cycles...
May 2, 2018: Pediatric Blood & Cancer
https://www.readbyqxmd.com/read/29697191/treatment-of-refractory-germ-cell-tumors-in-children-with-paclitaxel-ifosfamide-and-carboplatin-a-report-from-the-children-s-oncology-group-agct0521-study
#16
Farzana Pashankar, A Lindsay Frazier, Mark Krailo, Caihong Xia, Alberto S Pappo, Marcio Malogolowkin, Thomas A Olson, Carlos Rodriguez-Galindo
BACKGROUND: Paclitaxel, ifosfamide, cisplatin (TIP) is commonly used as salvage for malignant germ cell tumors (MGCT) in adults; however, additional administration of cisplatin at a young age could cause significant short- and long-term toxicities in a group of patients with high expected salvage. Because carboplatin has been shown to be effective in pediatric MGCT with less toxicity, the TIP regimen was modified by substituting carboplatin for cisplatin. METHODS: The Children's Oncology Group conducted a phase II trial between November 2007 and June 2011 evaluating "TIC" (paclitaxel 135 mg/m2 /day Day 1, ifosfamide 1,800 mg/m2 /dose Days 1-5 and carboplatin with AUC 6...
April 26, 2018: Pediatric Blood & Cancer
https://www.readbyqxmd.com/read/29697190/treatment-of-retinoblastoma-in-sub-saharan-africa-experience-of-the-paediatric-oncology-unit-at-gabriel-toure-teaching-hospital-and-the-institute-of-african-tropical-ophthalmology-bamako-mali
#17
Fousseyni Traoré, Fatou Sylla, Boubacar Togo, Bakarou Kamaté, Konimba Diabaté, Abdoul Aziz Diakité, Hawa Diall, Fatoumata Dicko, Mariam Sylla, Pierre Bey, Laurence Desjardins, Anne Gagnepain-Lacheteau, Carole Coze, Mhamed Harif, François Doz
BACKGROUND: Retinoblastoma (Rb) is the most common intraocular primary malignancy in children. In industrialised countries, the cure rate is about 95%. We present the results of a prospective study on the management of Rb in the paediatric oncology unit of Gabriel Touré Teaching Hospital and African Institute of Tropical Ophthalmology, from November 1, 2011 to December 31, 2015. PROCEDURE: The aims of this prospective study were to evaluate the treatment of localised Rb, ocular prosthesis after enucleation, conservative management for bilateral Rb as well as survival rates in all patients...
April 26, 2018: Pediatric Blood & Cancer
https://www.readbyqxmd.com/read/29693796/a-phase-1-study-of-cabozantinib-in-children-and-adolescents-with-recurrent-or-refractory-solid-tumors-including-cns-tumors-trial-advl1211-a-report-from-the-children-s-oncology-group
#18
Meredith K Chuk, Brigitte C Widemann, Charles G Minard, Xiaowei Liu, AeRang Kim, Melanie Brooke Bernhardt, Rachel A Kudgus, Joel M Reid, Stephan D Voss, Susan Blaney, Elizabeth Fox, Brenda J Weigel
BACKGROUND: We conducted a phase 1 trial to determine the maximum tolerated dose (MTD), toxicity profile, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary activity of cabozantinib in children with refractory or relapsed solid tumors. METHODS: Patients received cabozantinib tablets on a continuous dosing schedule in a rolling-six escalating phase 1 trial design. PK and PD studies were performed. RESULTS: Forty-one patients, median (range) age 13 (4-18) years, received cabozantinib to achieve a weekly cumulative dose equivalent to 30 (n = 6), 40 (n = 23)...
April 25, 2018: Pediatric Blood & Cancer
https://www.readbyqxmd.com/read/29691299/undifferentiated-sarcomas-in-children-harbor-clinically-relevant-oncogenic-fusions-and-gene-copy-number-alterations-a-report-from-the-children-s-oncology-group
#19
Theodore W Laetsch, Angshumoy Roy, Lin Xu, Jennifer O Black, Cheryl M Coffin, Yueh-Yun Chi, Jing Tian, Sheri L Spunt, Douglas S Hawkins, Julia A Bridge, D Williams Parsons, Stephen X Skapek
PURPOSE: A comprehensive analysis of the genomics of undifferentiated sarcomas (UDS) is lacking.  We analyzed copy number alterations and fusion status in patients with UDS prospectively treated on Children's Oncology Group protocol ARST0332. EXPERIMENTAL DESIGN: Copy number alterations were assessed by Oncoscan FFPE Express on 32 UDS. Whole-exome and transcriptome libraries from 8 tumors with sufficient archived material were sequenced on HiSeq (2x100 bp). Targeted RNA-sequencing using Archer chemistry was performed on two additional cases...
April 24, 2018: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/29683944/slco1b1-polymorphisms-are-associated-with-drug-intolerance-in-childhood-leukemia-maintenance-therapy
#20
İrem Eldem, Duygu Yavuz, Özge Cumaoğullari, Talia İleri, Elif Ünal İnce, Mehmet Ertem, Beyza Doğanay Erdoğan, Recep Bindak, Hilal Özdağ, N Lale Şatiroğlu-Tufan, L Zümrüt Uysal
BACKGROUND: Therapy discontinuations and toxicities occur because of significant interindividual variations in 6-mercaptopurine (6-MP) and methotrexate (MTX) response during maintenance therapy of childhood acute lymphoblastic leukemia (ALL). 6-MP/MTX intolerance in some of the patients cannot be explained by thiopurine S-methyl transferase (TPMT) gene variants. In this study, we aimed to investigate candidate pharmacogenetic determinants of 6-MP and MTX intolerance in Turkish ALL children...
April 20, 2018: Journal of Pediatric Hematology/oncology
keyword
keyword
18045
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"